Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 1
2005 2
2006 3
2007 3
2008 2
2009 8
2010 4
2011 10
2012 11
2013 8
2014 3
2015 4
2016 10
2017 12
2018 12
2019 15
2020 16
2021 18
2022 17
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Opportunities and challenges of bi-specific antibodies.
Segués A, Huang S, Sijts A, Berraondo P, Zaiss DM. Segués A, et al. Among authors: berraondo p. Int Rev Cell Mol Biol. 2022;369:45-70. doi: 10.1016/bs.ircmb.2022.05.001. Epub 2022 May 30. Int Rev Cell Mol Biol. 2022. PMID: 35777864 Review.
Cytokines in clinical cancer immunotherapy.
Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. Berraondo P, et al. Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Br J Cancer. 2019. PMID: 30413827 Free PMC article. Review.
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.
Teijeira Á, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, de Andrea C, Ochoa MC, Otano I, Etxeberria I, Andueza MP, Nieto CP, Resano L, Azpilikueta A, Allegretti M, de Pizzol M, Ponz-Sarvisé M, Rouzaut A, Sanmamed MF, Schalper K, Carleton M, Mellado M, Rodriguez-Ruiz ME, Berraondo P, Perez-Gracia JL, Melero I. Teijeira Á, et al. Among authors: berraondo p. Immunity. 2020 May 19;52(5):856-871.e8. doi: 10.1016/j.immuni.2020.03.001. Epub 2020 Apr 13. Immunity. 2020. PMID: 32289253 Free article.
IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy.
Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, Eguren-Santamaria I, Berraondo P, Schalper KA, de Andrea CE, Sanmamed MF, Melero I. Teijeira A, et al. Among authors: berraondo p. Clin Cancer Res. 2021 May 1;27(9):2383-2393. doi: 10.1158/1078-0432.CCR-20-1319. Epub 2020 Dec 29. Clin Cancer Res. 2021. PMID: 33376096 Review.
Revisiting Intracavitary Immunotherapy of Cancer.
Aranda F, Eguren-Santamaria I, Bella Á, Berraondo P, Melero I. Aranda F, et al. Among authors: berraondo p. Clin Cancer Res. 2022 May 13;28(10):1993-1995. doi: 10.1158/1078-0432.CCR-22-0201. Clin Cancer Res. 2022. PMID: 35247905
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, de Andrea C, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Llacer C, Alvarez M, de Luque V, Molina C, Teijeira A, Berraondo P, Melero I. Perez-Ruiz E, et al. Among authors: berraondo p. Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1. Nature. 2019. PMID: 31043740 Free article.
Novel strategies exploiting interleukin-12 in cancer immunotherapy.
Cirella A, Luri-Rey C, Di Trani CA, Teijeira A, Olivera I, Bolaños E, Castañón E, Palencia B, Brocco D, Fernández-Sendin M, Aranda F, Berraondo P, Melero I. Cirella A, et al. Among authors: berraondo p. Pharmacol Ther. 2022 Nov;239:108189. doi: 10.1016/j.pharmthera.2022.108189. Epub 2022 Apr 14. Pharmacol Ther. 2022. PMID: 35430292 Review.
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A, Herranz JM, Latasa MU, Arechederra M, Uriarte I, Pineda-Lucena A, Prosper F, Berraondo P, Alonso C, Sangro B, García Marin JJ, Martinez-Chantar ML, Ciordia S, Corrales FJ, Francalanci P, Alaggio R, Zucman-Rossi J, Indersie E, Cairo S, Domingo-Sàbat M, Zanatto L, Sancho-Bru P, Armengol C, Berasain C, Fernandez-Barrena MG, Avila MA. Clavería-Cabello A, et al. Among authors: berraondo p. J Hepatol. 2023 Oct;79(4):989-1005. doi: 10.1016/j.jhep.2023.05.031. Epub 2023 Jun 10. J Hepatol. 2023. PMID: 37302584 Free article.
Cellular immunotherapies for cancer.
Berraondo P, Labiano S, Minute L, Etxeberria I, Vasquez M, Sanchez-Arraez A, Teijeira A, Melero I. Berraondo P, et al. Oncoimmunology. 2017 May 2;6(5):e1306619. doi: 10.1080/2162402X.2017.1306619. eCollection 2017. Oncoimmunology. 2017. PMID: 28638729 Free PMC article. Review.
Druggable Targets in Cytokine Release Syndromes.
Luri-Rey C, Eguren-Santamaria I, Matos I, Berraondo P, Melero I. Luri-Rey C, et al. Among authors: berraondo p. Clin Cancer Res. 2023 Nov 1;29(21):4320-4322. doi: 10.1158/1078-0432.CCR-23-1975. Clin Cancer Res. 2023. PMID: 37656058
166 results